FierceBiotechFierceBiotechResearchFierceBiotechITFierceVaccinesFiercePharmaFiercePharmaManufacturing   FierceHealthcare

Free Newsletter

About | View Sample | Privacy

GE negotiating for Abbott diagnostics unit

Tools

Several news reports have surfaced that General Electric is close to a deal to buy the diagnostics unit of Abbott Laboratories for about $5 billion. A deal would greatly increase the size of GE's healthcare business, which has been focused on expanding its presence in IT as well as molecular diagnostics.

- read the AP's report on the talks

Related Articles:
JPMorgan, GE make healthcare acquisitions. Report
Abbott documents reveal plan to boost AIDS drug sales. Report


SHARE
WITH:
Email Twitter Facebook LinkedIn StumbleUpon
Get Your FREE FierceBiotech Email Newsletter:
Be the first to comment
More stories about Abbott Labs   HIV/AIDS   molecular diagnostics  

Comments

Comments from respective companies might not surface for sometime due to the ongoing due deligence. However, acquiring Abbott makes sense for GE with the following considerations;

1. Siemens acquires DPC & Bayer Diagnostics to become the only totally integrated diagnostics company with In Vivo & In Vitro capabilities.
2. The value chain for healthcare delivery is migrating towards much more holistic delivery of services.
3. Siemens to leverage its imaging strength and amalgmate with immuno & molecular diagnostics towards new molecular imaging Dx as well as LIS/ HIS.
4. Abbott is the world leader in Immunodiagnostics with its Architech platform & has a fair presence in Molecular Dx with Vysis platform.
5. Abbott acquisition will provide GE an edge over its arch-rival Siemens.

However, one needs to consider the emerging under-currents in the global pharma sector after experiencing the onslaught of generic competition, shrinking pipelines & reducing block-busters. The big pharma companies are either focusing on the niche-busters i.e. biotech & specialized therapeutics OR clinging on to Medical Devices & Diagnostics. These are the two business options with higher entry barriers.

Abbott has recently consolodited on its strategic roadmap towards Med Devices & Dx with Guidant Acquisition. Hence, any decision of let go the future growth avenue & 3rd largest segment among Devices & Dx i.e. Dx will be a choice well thought & weighed. The benefits for the sell of Dx unit would be far more bigger & strategic in nature for Abbott.

Post new comment

The content of this field is kept private and will not be shown publicly.

More information about formatting options

To combat spam, please enter the code in the image.